Statin potency comparison
Pro Research Analysisby 
Searched over 200M research papers
Statin Potency: Definitions and Common Types
Statins are classified by their potency, which refers to their ability to lower cholesterol levels. High-potency statins include atorvastatin and rosuvastatin, while low-potency statins include pravastatin, fluvastatin, pitavastatin, and simvastatin at lower doses 17.
Cardiovascular Outcomes: High vs. Low Potency Statins
Research comparing high- and low-potency statins in older adults found minimal differences in cardiovascular disease (CVD) outcomes and no significant difference in persistent physical disability. However, high-potency statins were marginally associated with a lower risk of fatal CVD events compared to low- or moderate-potency statins . In patients with a history of stroke or transient ischemic attack (TIA), use of moderate/high-potency statins was associated with reduced short- and long-term mortality, supporting current guidelines for secondary prevention .
Diabetes Risk and Glycemic Control with Statin Potency
Higher potency statins are linked to a moderate increase in the risk of new-onset diabetes compared to lower potency statins, especially in the first few months of use . In patients with type 2 diabetes, statin therapy in general led to a greater need for intensification of diabetes treatment, but this effect was less pronounced with lower-potency statins, which also showed a slight reduction in HbA1c and fasting glucose levels .
Adverse Effects: Kidney Injury and Myotoxicity
High-potency statins are associated with an increased risk of hospitalization for acute kidney injury, particularly within the first 120 days of treatment, compared to low-potency statins . Regarding muscle toxicity, the lactone forms of statins (regardless of potency) are significantly more potent in causing myotoxicity in human skeletal muscle cells than their acid forms, highlighting the importance of statin formulation in side effect profiles .
Other Health Outcomes: Glaucoma, Pneumonia, and Alzheimer’s Disease
No significant difference was found between high- and low-potency statins in the risk of developing open-angle glaucoma in a Japanese working-age population . For community-acquired pneumonia, higher potency statins were not associated with a decreased risk; in fact, they were linked to a slightly increased rate of hospitalization and fatal cases compared to lower potency statins . In Alzheimer’s disease, low-potency and hydrophilic statins (such as pitavastatin and rosuvastatin) were associated with lower odds of anti-Alzheimer’s medication use compared to high-potency or lipophilic statins (such as atorvastatin) .
Conclusion
High-potency statins may offer marginal benefits in reducing fatal cardiovascular events and mortality after stroke or TIA, but they are also associated with increased risks of new-onset diabetes and acute kidney injury compared to low-potency statins. For other outcomes such as glaucoma, pneumonia, and Alzheimer’s disease, low-potency or hydrophilic statins may be preferable. The choice of statin potency should be individualized, balancing cardiovascular benefits against potential risks, especially in populations at risk for diabetes or kidney injury 1345+4 MORE.
Sources and full results
Most relevant research papers on this topic
Comparison between high and low potency statins in the incidence of open-angle glaucoma: A retrospective cohort study in Japanese working-age population
High-potency statins show no significant association with an increased risk of glaucoma in Japanese working-age population.
Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
Lactone forms of statins have a significantly higher potency to induce myotoxicity in human skeletal muscle cells compared to their acid forms.
DOI